Marilynn Larkin

Men are less likely than women to receive an obesity diagnosis, be referred for treatment, or engage in treatment, but strategies to close the gap are emerging.

Endo-TAGSS is the first percutaneous intragastric trocar that enables minimally invasive pyloroplasty for patients who don’t respond to prokinetic and antiemetic medications.

October 21, 2026 The FDA has granted Breakthrough Device Designation to the Trans-Abdominal Gastric Surgical System (TAGSS; Endo-TAGSS) for use in patients with medically refractory gastroparesis.

Hibsago, the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B, reduces the amount of virus and hepatitis B surface antigen in the body.

Hibsago is the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B. It works by targeting the genetic instructions the virus uses to make copies of itself and viral proteins, helping to reduce the amount of virus and HBsAg in the body.

Use of AI scribes is climbing across Canada, and experts and surveys point to benefits as well as concerns about errors, consent, and accountability.

Diabetic peripheral neuropathy is among the most common and debilitating complications of type 2 diabetes, but early detection and effective treatments remain challenging.

October 23, 2026 Diabetic peripheral neuropathy (DPN) is among the most common and disabling complications of type 2 diabetes (T2D). Individuals

Diet is a cornerstone of diabetes management, but questions remain about which approaches work best.

Diet is a cornerstone of diabetes management, but questions remain about which approaches work best and whether benefits last once intensive support ends. Three studies presented at the